Nursing Edição Brasileira · Aug 27, 2026

Ovarian Rejuvenation with Platelet-Rich Plasma (prp): Reality or Promise?

By Cadore FG, Silva MB, Dolenkei N et al.

Ovarian aging and the consequent decline in follicular reserve represent significant obstacles in contemporary reproductive medicine, motivating the search for regenerative therapies that could restore fertility potential in women with premature ovarian failure or a diminished response to ovarian stimulation. Platelet-rich plasma (PRP), a concentrated source of autologous growth factors, has emerged as a promising experimental approach to so-called "ovarian rejuvenation," theoretically capable of reactivating dormant follicles and improving the ovulatory microenvironment through cell signaling and angiogenesis mechanisms. The objective of this work was to conduct a systematic review of the Brazilian literature on the clinical efficacy and safety of intraovarian PRP use in patients with ovarian insufficiency. The methodology was based on a search for Brazilian studies published in the last decade in databases such as SciELO and BVS. The results indicate that, although there are promising reports of increased anti-Müllerian hormone levels and improved response to ovarian stimulation, the data remain heterogeneous and of variable quality. It is concluded that ovarian rejuvenation with PRP remains at an experimental stage, serving more as a therapeutic promise than as an established standard of care, requiring rigorous randomized clinical trials to define its actual efficacy and guidelines for its application.

doi.org/10.36489/nursing.2026v32i340p20638-20641Open accessInterventions

AgingResearch.News